Phase
Condition
Cancer
Venous Thrombosis
Venous Thromboembolism
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Documentation of cancer.
The disease may be a solid tumor, Lymphoma or Multiple Myeloma. Pathology reports will be documented in the patient's chart and included in the data.
Age > 18 years
An acute, radiographically confirmed, de novo Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
No past medical history of a prior thrombus or known thrombophilia
Exclusion Criteria
Patients are not eligible for this study if they receive therapeutic doses of any heparin for more than 72 hours before randomization 31.
Already receiving oral anticoagulant therapy 31.
Severe renal impairment, calculated using the Cockcroft-Gault formula, defined as a creatinine clearance <30 mL/min 31.
Platelet count of less than 50,000 per cubic millimeter
Bleeding from the gastrointestinal tract that requires blood transfusion (s), intracranial bleeding or retroperitoneal bleeding.
An indication for thrombolysis
Allergy to iodine
Hereditary thrombophilia
Pregnancy
Likelihood of noncompliance
It is contraindicated to anticoagulate patients with brain metastasis secondary to melanoma, choriocarcinoma, renal cell and medullary thyroid carcinoma. If these patients have a Venous Thromboembolism (VTE), it is standard of care for these patients to have a CT of their head to evaluate if there is metastasis to the brain before they are anticoagulated 38. If these patients do have brain metastasis, they will not be included in the study.
Study Design
Study Description
Connect with a study center
North Shore University Hospital, Monter Cancer Center
Lake Success, New York 11042
United StatesSite Not Available
North Shore University Hospital
Manhasset, New York 11030
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.